CA2783858C - Method to use gene expression to determine likelihood of clinical outcome of renal cancer - Google Patents

Method to use gene expression to determine likelihood of clinical outcome of renal cancer Download PDF

Info

Publication number
CA2783858C
CA2783858C CA2783858A CA2783858A CA2783858C CA 2783858 C CA2783858 C CA 2783858C CA 2783858 A CA2783858 A CA 2783858A CA 2783858 A CA2783858 A CA 2783858A CA 2783858 C CA2783858 C CA 2783858C
Authority
CA
Canada
Prior art keywords
gene
lmnb1
patient
expression
genes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2783858A
Other languages
English (en)
French (fr)
Other versions
CA2783858A1 (en
Inventor
Wayne Cowens
Steven Shak
Audrey Goddard
Dejan Knezevic
Joffre Baker
Michael C. Kiefer
Tara Maddala
Frederick L. Baehner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genomic Health Inc
Original Assignee
Genomic Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genomic Health Inc filed Critical Genomic Health Inc
Priority to CA3128103A priority Critical patent/CA3128103C/en
Publication of CA2783858A1 publication Critical patent/CA2783858A1/en
Application granted granted Critical
Publication of CA2783858C publication Critical patent/CA2783858C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B99/00—Subject matter not provided for in other groups of this subclass
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N7/00—Computing arrangements based on specific mathematical models
    • G06N7/01—Probabilistic graphical models, e.g. probabilistic networks
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Theoretical Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medical Informatics (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Data Mining & Analysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mathematical Optimization (AREA)
  • Algebra (AREA)
CA2783858A 2010-01-11 2011-01-07 Method to use gene expression to determine likelihood of clinical outcome of renal cancer Active CA2783858C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3128103A CA3128103C (en) 2010-01-11 2011-01-07 METHOD FOR USING GENE EXPRESSION TO DETERMINE THE POSSIBILITY OF A CLINICAL OUTCOME OF KIDNEY CANCER

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29403810P 2010-01-11 2010-01-11
US61/294,038 2010-01-11
US34623010P 2010-05-19 2010-05-19
US61/346,230 2010-05-19
PCT/US2011/020596 WO2011085263A2 (en) 2010-01-11 2011-01-07 Method to use gene expression to determine likelihood of clinical outcome of renal cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3128103A Division CA3128103C (en) 2010-01-11 2011-01-07 METHOD FOR USING GENE EXPRESSION TO DETERMINE THE POSSIBILITY OF A CLINICAL OUTCOME OF KIDNEY CANCER

Publications (2)

Publication Number Publication Date
CA2783858A1 CA2783858A1 (en) 2011-07-14
CA2783858C true CA2783858C (en) 2021-09-14

Family

ID=44258831

Family Applications (3)

Application Number Title Priority Date Filing Date
CA2783858A Active CA2783858C (en) 2010-01-11 2011-01-07 Method to use gene expression to determine likelihood of clinical outcome of renal cancer
CA3256492A Pending CA3256492A1 (en) 2010-01-11 2011-01-07 Method to use gene expression to determine likelihood of clinical outcome of renal cancer
CA3128103A Active CA3128103C (en) 2010-01-11 2011-01-07 METHOD FOR USING GENE EXPRESSION TO DETERMINE THE POSSIBILITY OF A CLINICAL OUTCOME OF KIDNEY CANCER

Family Applications After (2)

Application Number Title Priority Date Filing Date
CA3256492A Pending CA3256492A1 (en) 2010-01-11 2011-01-07 Method to use gene expression to determine likelihood of clinical outcome of renal cancer
CA3128103A Active CA3128103C (en) 2010-01-11 2011-01-07 METHOD FOR USING GENE EXPRESSION TO DETERMINE THE POSSIBILITY OF A CLINICAL OUTCOME OF KIDNEY CANCER

Country Status (12)

Country Link
US (4) US9551034B2 (enExample)
EP (5) EP3561078A1 (enExample)
JP (5) JP6286124B2 (enExample)
AU (1) AU2011203977B2 (enExample)
CA (3) CA2783858C (enExample)
DK (1) DK3178944T3 (enExample)
ES (2) ES2741379T3 (enExample)
IL (6) IL219978A (enExample)
MX (3) MX341866B (enExample)
NZ (4) NZ705645A (enExample)
SG (1) SG181806A1 (enExample)
WO (1) WO2011085263A2 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011085263A2 (en) 2010-01-11 2011-07-14 Genomic Health, Inc. Method to use gene expression to determine likelihood of clinical outcome of renal cancer
IL243203A (en) 2010-07-27 2017-04-30 Genomic Health Inc Method for using gene expression to determine prognosis of prostate cancer
KR101857462B1 (ko) 2010-08-13 2018-05-14 소마로직, 인크. 췌장암 바이오마커 및 그것의 용도
WO2013016673A2 (en) * 2011-07-27 2013-01-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of dpep1 and tpx2 expression for evaluating treatment or survival time of patients with pancreatic ductal adenocarcinoma
CA2843756A1 (en) * 2011-08-22 2013-02-28 Somalogic, Inc. Renal cell carcinoma biomarkers and uses thereof
EP2771488B1 (en) 2011-10-24 2018-03-28 SignalChem Lifesciences Corporation Carbonic anhydrase ix-related markers and use thereof
HK1201881A1 (en) 2012-01-31 2015-09-11 Genomic Health, Inc. Gene expression profile algorithm and test for determining prognosis of prostate cancer
SG11201506987VA (en) * 2013-05-30 2015-10-29 Genomic Health Inc Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer
EP3047040B1 (en) * 2013-09-17 2019-12-11 Lucence Life Sciences Pte Ltd. Multigene assay for prognosis of renal cancer
WO2016034611A1 (en) * 2014-09-02 2016-03-10 Max-Delbrück-Centrum für Molekulare Medizin Antisense oligonucleotides targeting 3'utr region of a20
JP6638128B2 (ja) * 2014-10-30 2020-01-29 公立大学法人福島県立医科大学 腎がんの悪性度の検査マーカー及び検査方法
WO2016126883A1 (en) * 2015-02-03 2016-08-11 Cedars-Sinai Medical Center Biomarker based prognostic model for predicting overall survival in patients with metastatic clear cell kidney cancer
GB201616912D0 (en) 2016-10-05 2016-11-16 University Of East Anglia Classification of cancer
AU2018228873A1 (en) 2017-03-01 2019-08-29 Genentech, Inc. Diagnostic and therapeutic methods for cancer
WO2018161027A1 (en) * 2017-03-03 2018-09-07 Oregon State University Antisense antibacterial compounds and methods
US10636512B2 (en) 2017-07-14 2020-04-28 Cofactor Genomics, Inc. Immuno-oncology applications using next generation sequencing
US11335464B2 (en) * 2018-01-12 2022-05-17 Siemens Medical Solutions Usa, Inc. Integrated precision medicine by combining quantitative imaging techniques with quantitative genomics for improved decision making
CA3105292A1 (en) * 2018-08-10 2020-02-13 Omniseq, Inc. Methods and systems for assessing proliferative potential and resistance to immune checkpoint blockade
WO2020085936A1 (ru) * 2018-10-24 2020-04-30 Общество С Ограниченной Ответственностью "Онкобокс" Тест-классификатор клинического ответа на лечение сорафенибом индивидуальных пациентов с раком почки
US11845989B2 (en) 2019-01-23 2023-12-19 Regeneron Pharmaceuticals, Inc. Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors
JP2022523301A (ja) 2019-01-23 2022-04-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッド アンジオポエチン様７（ａｎｇｐｔｌ７）阻害剤による眼疾患の治療
WO2021030604A1 (en) * 2019-08-14 2021-02-18 University Of Massachusetts Urinary rna signatures in renal cell carcinoma (rcc)
AU2022226164A1 (en) 2021-02-26 2023-08-03 Regeneron Pharmaceuticals, Inc. Treatment of inflammation with glucocorticoids and angiopoietin-like 7 (angptl7) inhibitors
CN113025716A (zh) * 2021-03-02 2021-06-25 北京大学第一医院 一种用于人肿瘤分级的基因组合及其用途
CN113817816A (zh) * 2021-10-08 2021-12-21 济南艾迪康医学检验中心有限公司 检测epas1基因突变的引物、试剂盒和方法
WO2023080900A1 (en) * 2021-11-05 2023-05-11 Genentech, Inc. Methods and compositions for classifying and treating kidney cancer
CN118711678B (zh) * 2024-08-22 2025-12-12 暨南大学附属第一医院（广州华侨医院） 一种肾透明细胞肿瘤预测方法、装置、设备及存储介质

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5322770A (en) 1989-12-22 1994-06-21 Hoffman-Laroche Inc. Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
US7135314B1 (en) * 1997-04-17 2006-11-14 Cell Therapeutics, Inc. Human phosphatidic acid phosphatase
WO2001051635A2 (en) * 2000-01-13 2001-07-19 Genentech, Inc. Novel stra6 polypeptides
DE10126344A1 (de) * 2000-07-14 2002-01-24 Max Planck Gesellschaft Apoptose-induzierende DNA-Sequenzen
WO2002027028A1 (en) * 2000-09-28 2002-04-04 Atairgin Technologies, Inc. A method of determining tumor characteristics by determining abnormal copy number or expression level of lipid-associated genes
US20030109434A1 (en) * 2001-03-19 2003-06-12 Corixa Corporation Compositions and methods for the therapy and diagnosis of kidney cancer
WO2002079411A2 (en) * 2001-03-29 2002-10-10 Van Andel Institute Microarray gene expression profiling in clear cell renal cell carcinoma: prognosis and drug target identification
JP2005500832A (ja) 2001-06-18 2005-01-13 ロゼッタ・インファーマティクス・インコーポレーテッド 乳癌患者の診断および予後
US7470509B2 (en) 2002-02-08 2008-12-30 Millennium Pharmaceuticals, Inc. Compositions and methods for the identification, assessment, prevention and therapy of ovarian cancer
DK1918386T3 (da) 2002-03-13 2012-01-02 Genomic Health Inc Genekspressionsprofiler i biopsier af tumorvæv
WO2004032842A2 (en) * 2002-10-04 2004-04-22 Van Andel Research Institute Molecular sub-classification of kidney tumors and the discovery of new diagnostic markers
US7611839B2 (en) * 2002-11-21 2009-11-03 Wyeth Methods for diagnosing RCC and other solid tumors
CA2523798A1 (en) * 2003-04-29 2004-11-11 Wyeth Methods for prognosis and treatment of solid tumors
CA2530738C (en) 2003-06-24 2020-01-21 Genomic Health, Inc. Prediction of likelihood of cancer recurrence
WO2005005661A2 (en) 2003-07-02 2005-01-20 Novartis Ag Genes regulated in ovarian cancer as prognostic and therapeutic targets
US20050002904A1 (en) * 2003-07-03 2005-01-06 Wary Kishore K. Uses of vascular endothelial growth factor and type I collagen inducible protein (VCIP)
DK1644858T3 (da) 2003-07-10 2018-01-22 Genomic Health Inc Funktionel beklædning med mindst et yderlag og en indermembran.
US20050130193A1 (en) 2003-09-10 2005-06-16 Luxon Bruce A. Methods for detecting, diagnosing and treating human renal cell carcinoma
JP2005211023A (ja) * 2004-01-30 2005-08-11 Hayashibara Biochem Lab Inc 腎細胞癌の転移若しくは再発の可能性を予測する方法
EP1737980A2 (en) 2004-04-09 2007-01-03 Fondazione IRCCS Istituto Nazionale dei Tumori Gene expression markers for predicting response to chemotherapy
US20070224596A1 (en) * 2004-04-09 2007-09-27 Mariana Nacht Compositions and methods for the modifying hypoxia induced gene regulation
CN101023185A (zh) * 2004-05-27 2007-08-22 威特克斯医药股份有限公司 用于监测impdh通路抑制作用的生物学标记
US7587279B2 (en) 2004-07-06 2009-09-08 Genomic Health Method for quantitative PCR data analysis system (QDAS)
US20080119367A1 (en) * 2004-12-17 2008-05-22 Mayo Foundation For Medical Education And Research Prognosis of Renal Cell Carcinoma
US20090258002A1 (en) 2005-02-01 2009-10-15 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services Biomarkers for Tissue Status
US20090061423A1 (en) 2005-02-18 2009-03-05 Wyeth Pharmacogenomic markers for prognosis of solid tumors
WO2006124836A1 (en) 2005-05-13 2006-11-23 Duke University Gene expression signatures for oncogenic pathway deregulation
WO2006124022A1 (en) * 2005-05-13 2006-11-23 Vanandel Research Institute Microarray gene expression profiling in subtypes of clear cell renal cell carcinoma
US20070037186A1 (en) * 2005-05-20 2007-02-15 Yuqiu Jiang Thyroid fine needle aspiration molecular assay
EP1899486A4 (en) * 2005-06-08 2009-07-22 Millennium Pharm Inc METHOD FOR IDENTIFYING, ASSESSING AND TREATING PATIENTS IN CANCER THERAPY
WO2006135886A2 (en) * 2005-06-13 2006-12-21 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2006138275A2 (en) * 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
JP4312256B2 (ja) * 2005-06-15 2009-08-12 ファイザー・リミテッド 寄生生物に対して使用する置換アリールピラゾール
EP1930426A4 (en) 2005-09-02 2009-04-29 Toray Industries COMPOSITION AND METHOD FOR DIAGNOSING KIDNEY CANCER AND ASSESSING THE PROGNOSIS OF A KIDNEY CANCER PATIENTS
US8343738B2 (en) 2005-09-14 2013-01-01 Human Genetic Signatures Pty. Ltd. Assay for screening for potential cervical cancer
EP2332984A3 (en) * 2005-09-30 2011-10-12 Universiteit Maastricht Tumor angiogenesis associated genes and a method for their identification
EP1777523A1 (en) 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
EP1960551A2 (en) 2005-12-01 2008-08-27 Medical Prognosis Institute Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
US8445198B2 (en) * 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
WO2007111733A2 (en) 2005-12-16 2007-10-04 Genentech, Inc. Method for diagnosing, prognosing and treating glioma
US20080242606A1 (en) * 2006-06-06 2008-10-02 Zhong Jiang Use of IMP3 as a Prognostic Marker for Cancer
MX2009001489A (es) * 2006-08-10 2009-02-18 Millennium Pharm Inc Para la identificacion, valoracion y tratamiento de pacientes con terapia de cancer.
US8450057B2 (en) 2006-08-14 2013-05-28 The Brigham And Women's Hospital, Inc. Diagnostic tests using gene expression ratios
US9034574B2 (en) 2006-12-27 2015-05-19 The Johns Hopkins University Agents for reversing epigenetic silencing of genes
US20080286273A1 (en) 2007-05-02 2008-11-20 Siemens Medical Solutions Usa, Inc. Knowledge-Based Proliferation Signatures and Methods of Use
EP1990417A1 (en) 2007-05-11 2008-11-12 Universität Bayreuth Archaeal plasmid vector system
WO2009105640A1 (en) 2008-02-22 2009-08-27 Virginia Commonwealth University Signatures associated with rejection or recurrence of cancer
CA2743473C (en) 2008-11-17 2022-06-14 Veracyte, Inc. Methods and compositions of molecular profiling for disease diagnostics
AU2010264763B2 (en) * 2009-06-26 2015-07-23 Noviogendix Research B.V. Molecular markers in kidney cancer
US20110123990A1 (en) 2009-11-23 2011-05-26 Baker Joffre B Methods To Predict Clinical Outcome Of Cancer
WO2011085263A2 (en) 2010-01-11 2011-07-14 Genomic Health, Inc. Method to use gene expression to determine likelihood of clinical outcome of renal cancer
WO2012174282A2 (en) 2011-06-16 2012-12-20 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Biomarker compositions and methods
CA2843756A1 (en) 2011-08-22 2013-02-28 Somalogic, Inc. Renal cell carcinoma biomarkers and uses thereof

Also Published As

Publication number Publication date
JP2021177761A (ja) 2021-11-18
IL251635B (en) 2018-04-30
WO2011085263A3 (en) 2012-01-12
MX2012007882A (es) 2012-08-03
ES2741379T3 (es) 2020-02-10
JP2019162150A (ja) 2019-09-26
EP3561078A1 (en) 2019-10-30
NZ617003A (en) 2015-04-24
IL280689A (en) 2021-03-25
IL219978A (en) 2017-04-30
NZ600268A (en) 2014-08-29
MX375138B (es) 2025-03-06
MX2020009704A (es) 2020-10-07
SG181806A1 (en) 2012-07-30
NZ719474A (en) 2018-07-27
JP7307602B2 (ja) 2023-07-12
US20170121780A1 (en) 2017-05-04
EP3831964B1 (en) 2025-04-16
EP2524055A2 (en) 2012-11-21
US11776664B2 (en) 2023-10-03
US10892038B2 (en) 2021-01-12
IL262100A (en) 2018-11-29
JP2016174600A (ja) 2016-10-06
CA3128103C (en) 2025-11-18
MX341866B (es) 2016-09-06
CA3256492A1 (en) 2025-11-29
US12412642B2 (en) 2025-09-09
JP6546214B2 (ja) 2019-07-17
ES3027507T3 (en) 2025-06-16
US20240096451A1 (en) 2024-03-21
DK3178944T3 (da) 2019-08-12
EP3029155A3 (en) 2016-08-31
EP3831964A2 (en) 2021-06-09
JP6286124B2 (ja) 2018-02-28
US20220051755A9 (en) 2022-02-17
CA2783858A1 (en) 2011-07-14
IL219978A0 (en) 2012-07-31
JP7385630B2 (ja) 2023-11-22
JP2013516195A (ja) 2013-05-13
IL270151B (en) 2021-03-25
US20210166790A1 (en) 2021-06-03
IL262100B (en) 2019-11-28
IL280689B (en) 2022-01-01
CA3128103A1 (en) 2011-07-14
EP3831964A3 (en) 2021-10-20
IL256335B (en) 2018-12-31
US20110171633A1 (en) 2011-07-14
NZ705645A (en) 2016-05-27
AU2011203977A1 (en) 2012-06-21
AU2011203977B2 (en) 2015-02-05
IL251635A0 (en) 2017-06-29
EP3178944A3 (en) 2017-09-13
EP3178944A2 (en) 2017-06-14
EP3178944B1 (en) 2019-05-15
JP2017148059A (ja) 2017-08-31
EP3029155A2 (en) 2016-06-08
EP2524055A4 (en) 2013-06-05
WO2011085263A2 (en) 2011-07-14
US9551034B2 (en) 2017-01-24

Similar Documents

Publication Publication Date Title
US12412642B2 (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
US20220396842A1 (en) Method for using gene expression to determine prognosis of prostate cancer
US20110123990A1 (en) Methods To Predict Clinical Outcome Of Cancer
AU2015227398B2 (en) Method for using gene expression to determine prognosis of prostate cancer
AU2019268079B2 (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
HK40052322B (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
HK40052322A (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
HK40016195A (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
HK1263320B (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
HK1263320A1 (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
HK1235085A1 (en) Method for using gene expression to determine prognosis of prostate cancer
HK1175820A (en) Methods to predict clinical outcome of cancer

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20151201